| 生物制剂治疗银屑病共病研究进展 |
| |
| 引用本文： | 胡中慧,孙青. 生物制剂治疗银屑病共病研究进展[J]. 中国麻风皮肤病杂志, 2021, 37(7): 471-476. DOI: 10.12144/zgmfskin202107471 |
| |
| 作者姓名： | 胡中慧 孙青 |
| |
| 作者单位： | 山东大学齐鲁医院皮肤科，济南，250012 |
| |
| 摘 要： | 银屑病是一种常见的免疫介导的慢性炎症性疾病，与之相关的共病包括银屑病关节炎、心血管疾病、代谢综合征、炎症性肠病和心理疾病等。由于银屑病及其共病之间可能存在共同的致病途径，抑制相应免疫反应靶点的生物制剂可以通过改变全身炎症状态而对其共病产生影响。本文就生物制剂对银屑病共病治疗的应用进展进行综述。
|
| 关 键 词： | 生物制剂 银屑病 共病 |
Update of biological agents in the treatment of psoriasis comorbidities |
| |
| HU Zhonghui,SUN Qing. Update of biological agents in the treatment of psoriasis comorbidities[J]. China Journal of Leprosy and Skin Diseases, 2021, 37(7): 471-476. DOI: 10.12144/zgmfskin202107471 |
| |
| Authors: | HU Zhonghui SUN Qing |
| |
| Affiliation: | Department of Dermatology, Qilu Hospital of Shandong University, Jinan 250012, China |
| |
| Abstract: | Psoriasis is a common, chronic inflammatory disease with a variety of comorbidities involving psoriatic arthritis (PsA), cardiovascular diseases, metabolic syndrome (MS), inflammatory bowel disease (IBD) and psychological disease. Psoriasis and its comorbidities may share a common pathogenic pathway, so biological agents which are designed to inhibit specific molecular targets of immune responses can have an impact on comorbidities by changing systemic inflammatory state. The update of the treatment of biological agents on psoriasis comorbidities is reviewed in this paper. |
| |
| Keywords: | biological agents psoriasis comorbidities |
| 本文献已被 CNKI 等数据库收录！ |
| 点击此处可从《中国麻风皮肤病杂志》浏览原始摘要信息 |
|
点击此处可从《中国麻风皮肤病杂志》下载免费的PDF全文 |
